TAG | FrontPoint Partners LLC
Former Hedge Fund Portfolio Manager Charged With Insider Trading by SEC. Hedge Fund to Pay $33 Million.
Comments off · Posted by admin in FINRA
Washington, D.C. — It was announced April 13, 2011 on The Securities and Exchange Commission’s (SEC) website that a former hedge fund portfolio manager was charged with insider trading in a bio-pharmaceutical company based on confidential information about negative results of the company’s clinical drug trial.
We learn from the SEC website article that the SEC alleges that Dr. Joseph F. “Chip” Skowron, a former portfolio manager for six health care-related hedge funds affiliated with FrontPoint Partners LLC, sold hedge fund holdings of Human Genome Sciences Inc. (HGSI) based on a tip he received unlawfully from a medical researcher overseeing the drug trial. HGSI’s stock fell 44 percent after it publicly announced negative results from the trial of Albumin Interferon Alfa 2-a (Albuferon), and the hedge funds avoided at least $30 million in losses.
“It’s a prescription for an SEC enforcement action to illegally trade on confidential clinical trial information from doctors and other purported consultants,” said Lorin L. Reisner, Deputy Director of the SEC’s Enforcement Division.
The SEC previously charged – Dr. Yves M. Benhamou – who illegally tipped Skowron with the non-public information and received envelopes of cash in return according to the SEC’s amended complaint filed today in federal court in Manhattan to additionally charge Skowron. The hedge funds, which have been charged as relief defendants in the SEC’s amended complaint, have agreed to pay $33 million to settle the charges.
Also, Cheryl Scarboro, Chief of the Enforcement Division’s FCPA Unit, added, “Skowron attempted to game the markets and buy the silence of his tipper. His sale of his hedge funds’ entire position in HGSI stock before the announcement of negative news is precisely the sort of conduct that telegraphs insider trading.”
Also on April 13, 2011, the U.S. Attorney’s Office for the Southern District of New York announced criminal charges against Skowron. According to the SEC’s amended complaint, Benhamou served on the Steering Committee overseeing HGSI’s trial for Albuferon, a potential drug to treat Hepatitis C. While serving on the Steering Committee, Benhamou provided consulting services to Skowron through an expert networking firm. But over time, he and Skowron developed a friendship. By April 2007, many of their communications were independent of the expert networking firm. Benhamou tipped Skowron with material, non-public information about the trial as he learned of negative developments that occurred during Phase 3 of the trial.
In the SEC’s amended complaint, Skowron gave Benhamou an envelope of containing 5,000 Euros while they were attending a medical conference in Barcelona, Spain in April 2007. The cash was in appreciation for Benhamou’s work as a consultant. In February 2008, after the illegal HGSI trades were completed, Skowron asked Benhamou to lie about his communications with Skowron, which he did. In late February 2008, Skowron met Benhamou in Boston and attempted to hand him a bag containing cash in appreciation for his tips on the Albuferon trial and his continued silence. Benhamou refused the cash. However, while attending a medical conference in Milan, Italy in April 2008, Skowron gave Benhamou another envelope containing at least $10,000 in cash that Benhamou accepted.
Also, the SEC alleges that Skowron acted on confidential information he received from Benhamou prior to the public announcement and ordered the sale of the entire position in HGSI stock – approximately six million shares held by the six health-care related funds that Skowron co-managed. These sales occurred during the six-week period prior to HGSI’s public announcement. Skowron caused the hedge funds to sell two million shares in a block trade just before the markets closed Jan. 22, 2008. Changes to the trial resulting from the negative developments were announced publicly on January 23. When HGSI’s share price dropped 44 percent by the end of that day, the hedge funds avoided losses of at least $30 million.
It was announced that the SEC is seeking permanent injunctions, disgorgement of any ill-gotten gains with prejudgment interest, and financial penalties against Skowron and Benhamou. Simultaneous with the filing of the SEC’s amended complaint, the six hedge funds named as relief defendants agreed to settle with the Commission and pay disgorgement of $29,017,156.00 plus prejudgment interest of $4,003,669.00 without admitting or denying the allegations. The proposed settlement is subject to court approval.
Call a Securities Arbitration Lawyer for a free consultation on how to recover your losses. To speak with an attorney, call 888-760-6552, or visit www.stockmarketlawsuit.com. Soreide Law Group, PLLC., representing investors nationwide before FINRA the Financial Industry Regulatory Authority.
Albuferon drug trials · Albumin Interferon Alfa 2-a · bio-pharmaceutical hedge fund · Chip Skowron · Dr Joseph F "Chip" Skowron · Dr Yves M Benhamou · Financial Industry Regulatory Authority · FINRA · fort lauderdale securities fraud lawyer · fort lauderdale securities lawyer · FrontPoint Partners LLC · Ft. Lauderdale Securities Lawyer · game the market · health related hedge funds · hedge fund scams · hedge funds · hep c new drug hedge fund · Hepatitis C drug hedge fund · HGSI · Human Genome Sciences Inc · illegal tips to hedge funds · investment fraud · manipulating hedge fund · medical hedge funds false information · negative results in clinical drug trial from drug company in hedge fund · pay-off for tips on hedge funds · SEC · Securities and Exchange Commission · securities arbitraton lawyer · securities fraud lawyer · Soreide Law Group PLLC · Stock fraud lawyer · stock loss · trading on confidential clinical trial information · unauthorized trades